Cold Agglutinin Disease Market to Exhibit Massive Growth at a CAGR of 28% in the 7MM for the Study Period of 2019-32 | DelveInsight

The Cold Agglutinin Disease (CAD) market is expected to grow significantly owing to an increase in upcoming novel treatment options, increasing Cold Agglutinin Disease market size due to increasing prevalence, increasing global healthcare investment and funding, and the ongoing development of precision medicine.

LAS VEGAS, March 30, 2022 /PRNewswire/ -- DelveInsight's Cold Agglutinin Disease Market Insights report proffers a detailed comprehension of Cold Agglutinin Disease market size by treatment, epidemiology, emerging therapies, Cold Agglutinin Disease market share of the individual therapies, current and forecasted Cold Agglutinin Disease market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the salient features from the Cold Agglutinin Disease Market Report: 

• The total Cold Agglutinin Disease market size was found to be USD 61 million in 2021 in the 7MM and is expected to rise during the study period 2019-2032.
• Key Cold Agglutinin Disease companies currently working in the market include names such as Sanofi, Bioverativ, Sobi, Apellis Pharmaceuticals, Novartis, Incyte Corporation, and others are developing Cold Agglutinin Disease treatment therapies.
• The Cold Agglutinin Disease pipeline therapies include Sutimlimab, APL-2, Iptacopan, Parsaclisib, SAR445088, and others that are expected to launch in the study period 2019-32.
• The total Cold Agglutinin Disease market size in the United States accounted for USD 36 million in 2021 which is also expected to rise during the study period.
• The increasing awareness of the disease, availability of B-cell-directed therapies, assisted by active research in the complement pathway, along with the expected launch of complement inhibitors with good supply chains and supportive state-reimbursement policies are expected to fuel the Cold Agglutinin Disease market in near future.

For further information on Market Impact by Therapies, Download the Cold Agglutinin Disease Market sample @ Cold Agglutinin Disease Report Sample 

What is Cold Agglutinin Disease?

Cold Agglutinin Disease (CAD) is an uncommon autoimmune hemolytic anemia in which a well-defined, clonal low-grade lympho-proliferative disorder of the bone marrow results in erythrocyte destruction mediated by the classical complement pathway. It is mediated by cold agglutinins (CA), without any underlying disease such as aggressive lymphoma, other overt malignancies, or specific infections. CA are able to agglutinate red blood cells (RBC) at an optimum temperature of 3–4°C, but are also active at higher temperatures, depending on the thermal amplitude. Cold Agglutinin Disease symptoms get worse in cold weather.

Cold Agglutinin Disease Epidemiology Segmentation

According to Delveinsight's Analysis, in the year 2021, the total Cold Agglutinin Disease prevalent cases was 13 thousand cases in the 7MM which are expected to grow during the study period.

Also, DelveInsight analysts estimate that in the US, the total number of diagnosed Cold Agglutinin Disease cases were found to be 4 thousand cases in the year 2021 which are expected to grow in the coming years.

The Cold Agglutinin Disease Market Report proffers epidemiological analysis for the study period 2019-30 in the 7MM segmented into:

• Total Prevalent Cases of Cold Agglutinin Disease
• Total Diagnosed Cases of Cold Agglutinin Disease
• Total Gender-specific Cases of Cold Agglutinin Disease
• Total Type-specific Cases of Cold Agglutinin Disease, and 
• Total Treated Cases of Cold Agglutinin Disease

Know-how Cold Agglutinin Disease Epidemiological Trends are going to look like in 2032 for the 7 MM by downloading @ Cold Agglutinin Disease Epidemiological Insights

Cold Agglutinin Disease Market Outlook

Cold Agglutinin Disease treatment depends on the severity of the clinical symptoms, as determined by the characteristics of the antibody, and the presence of associated diseases. The current therapeutic Cold Agglutinin Disease market is dominated by non-pharmacological (cold avoidance) and pharmacological management. Avoidance of cold exposure, particularly to the head, face, and extremities, is important to decrease hemolysis and circulatory symptoms.

Currently, there are no clinically FDA-approved symptomatic Cold Agglutinin Disease treatments available.

Corticosteroids, alkylating agents, purine nucleoside analogs, and majorly biologics, such as Rituximab monotherapy or combination therapy (Fludarabine and Rituximab, Bendamustine and Rituximab) and others are the major therapeutic line of Cold Agglutinin Disease treatment.

Plasmapheresis is a temporary but effective method to remove cold agglutinins, primarily immunoglobulin (Ig) M autoantibodies, from the plasma. This procedure is performed only in case of emergencies when it is inappropriate to wait for the immunosuppressive drugs to produce an effect. Blood transfusions may be required in emergency cases with severe hemolysis precipitated by infection or cold during the winter months. In some countries, therapy with corticosteroids remains frequently used in clinical practice for Cold Agglutinin Disease.

Discover more about which therapy set to grab substantial Cold Agglutinin Disease market share @ Cold Agglutinin Disease Market Share 

Cold Agglutinin Disease Market Dynamics

The Cold Agglutinin Disease market is anticipated to surge in the coming years owing to certain factors such as an increase in upcoming novel treatment options with a novel mechanism of action, increasing Cold Agglutinin Disease market size due to increasing prevalence, increasing global healthcare investment, and funding, and the ongoing development of precision medicine. 

The increasing awareness of the disease, availability of B-cell-directed therapies, assisted by active research in the complement pathway, along with the expected launch of complement inhibitors with good supply chains and supportive state-reimbursement policies are expected to fuel the Cold Agglutinin Disease market in near future. In addition to that, a less competitive scenario in the Cold Agglutinin Disease market due to perks related to rare diseases act as major boosters in the Cold Agglutinin Disease market.

Currently only one drug has been approved for the treatment of this disease, due to which, the Cold Agglutinin Disease market is filled with the paucity of disease understanding, limited epidemiological studies, and limited therapeutic options. There is a high unmet need to establish suitable diagnostic criteria and increasing knowledge of the clinical features seen in many patients may help increase doctors' awareness and facilitate correct diagnosis, these factors might hinder the growth of the Cold Agglutinin Disease market. Additionally, lack of robust developmental pipeline, limitations related to complement inhibitors as well as some limitations of B-cell-directed therapies might serve as some major setbacks to the Cold Agglutinin Disease market rise in the coming years.

The Cold Agglutinin Disease market landscape has been severely lacking in any approved therapeutic agents. Therefore, the recent approval of the drug sutimlimab, and the promising new drugs under development, such as pegcetacoplan, directed to inhibit the classical pathway complement activation, will have a huge impact on the treatment market of Cold Agglutinin Disease. Since, approval of the first drug in a disease area or drug class, such as sutimlimab in Cold Agglutinin Disease area, is likely to stimulate future innovation by sending a positive signal to innovators and expanding the patient population. Additionally, market size may increase following the first drug's approval. The arrival of a disease-modifying therapy will strengthen incentives for patients to seek a diagnosis and thus enter the market for treatment.

Know which Cold Agglutinin Disease therapy is expected to score the touchdown first @ Cold Agglutinin Disease Market Landscape and Forecast

Scope of the Cold Agglutinin Disease Market Report

• Study Period: 2019-32
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cold Agglutinin Disease Companies: Sanofi, Bioverativ, Sobi, Apellis Pharmaceuticals, Novartis, Incyte Corporation
• Key  Cold Agglutinin Disease Pipeline Therapies: Sutimlimab, APL-2, Iptacopan, Parsaclisib, SAR445088
• Therapeutic Assessment:  Cold Agglutinin Disease current marketed and emerging therapies
• Market Dynamics:  Cold Agglutinin Disease market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• KOL's views
• Analyst's views
• Market Access and Reimbursement

Discover more about the future market share of Cold Agglutinin Disease treatment therapies @ Cold Agglutinin Disease Market Forecast

Table of Contents 

Get in touch with our Business executive @ Cold Agglutinin Disease Market Landscape Analysis 

Related Reports

Warm Autoimmune Hemolytic Anemia Pipeline

DelveInsight's, "Warm Autoimmune Hemolytic Anemia Pipeline Insights, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Warm Autoimmune Hemolytic Anemia pipeline landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further covers key Warm Autoimmune Hemolytic Anemia companies involved such as Immunovant Sciences GmbH, Apellis Pharmaceuticals, Bioverativ, and others.

Warm Autoimmune Hemolytic Anemia Epidemiology 

DelveInsight's 'Warm Autoimmune Hemolytic Anemia Epidemiology Forecast to 2030' report delivers an in-depth understanding of Warm autoimmune hemolytic anemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Iron Deficiency Anemia Market 

DelveInsight's 'Iron Deficiency Anemia Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the IDA, historical and forecasted epidemiology, as well as the IDA market trends, market drivers, market barriers, and key Iron Deficiency Anemia companies, involved such as Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysis, and others.

Iron Deficiency Anemia Epidemiology 

DelveInsight's 'Iron Deficiency Anemia Epidemiology Forecast to 2030' report delivers an in-depth understanding of the IDA across the several selected cancer types, historical and forecasted IDA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anemia in Chronic Kidney Disease Pipeline

DelveInsight's, "Anemia in Chronic Kidney Disease Pipeline Insights, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Anemia in Chronic Kidney Disease pipeline landscape. The report also covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers key Anemia in Chronic Kidney Disease companies involved such as Pieris Pharmaceuticals, Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and several others.

Aplastic Anemia Pipeline

DelveInsight's, "Aplastic Anemia Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in the Aplastic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers key Aplastic Anemia companies involved such as Pfizer, Regeneron Pharmaceuticals, Regen BioPharma, Omidubicel, Cellenkos, Hemogenyx, and many others.

Browse Through Our Blog Posts

• Warm Autoimmune Hemolytic Anemia: A less prevalent disease with prevailing unmet needs
• Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030
• Warm Autoimmune Hemolytic Anemia Epidemiology forecast segmentation, treatment approaches, and WAIHA market forecast
• Overcoming the prevailing unmet needs in Beta-Thalassemia Market

Assessing leakage for application of strategic counter by Competitive Intelligence

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us
Shruti Thakur 
[email protected] 
+1(919)321-6187 
www.delveinsight.com

SOURCE DelveInsight Business Research, LLP